{
  "first_published_at": "2009-12-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087718", 
  "title": "Warfarin: product information to be amended to give clearer, up-to-date advice", 
  "tags": "{\"parsed_therapeutic\": [\"cardiovascular-disease-lipidology\", \"haematology\", \"dentistry\"], \"Audience:\": [\"Primary care\", \"Secondary care\", \"Dentists\"], \"Therapeutic area:\": [\"Cardiovascular disease and lipidology\", \"Haematology\"]}", 
  "_document_number": 226, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cardiovascular-disease-lipidology", 
    "haematology", 
    "dentistry"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Warfarin: product information to be amended to give clearer, up-to-date advice</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: December 2009</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--We continue to receive a substantial number of serious and fatal adverse event reports for warfarin through our Yellow Card Scheme.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>We continue to receive a substantial number of serious and fatal adverse event reports for <strong>warfarin</strong> through our Yellow Card Scheme.</p><p>We have recently reviewed the safety information for warfarin products to assess whether it is in line with information from Yellow Card reports, the current medical literature, and with current practice guidance. No new safety issues were identified during this review; however, the Summaries of Product Characteristics (SPCs) for all warfarin products are to be amended to give clearer and up-to-date advice to healthcare professionals. This update will also result in improved patient leaflets to ensure patients have consistent and appropriate information on this important medicine.</p><p>In particular, the core SPC provides advice on:</p><ul>\r\n\t\t\t<li>Timing of warfarin treatment after ischaemic stroke</li>\r\n\t\t\t<li>Management of the patient before surgical or dental procedures</li>\r\n\t\t\t<li>Patients at particular risk of haemorrhage</li>\r\n\t\t\t<li>Interactions with herbal products, foods, and food supplements</li>\r\n\t\t\t<li>Management of patients with significantly raised INR and/or haemorrhage</li></ul><p>The updated warfarin core safety information, along with further information on the review, is available in a <a href=\"http://http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON065505\" target=\"_blank\">public assessment report</a> on our website. In particular, healthcare professionals should ensure that they understand the contraindications to warfarin therapy, the relevant warnings, and the clinically significant drug interactions.</p><p>Serious and unexpected adverse effects relating to warfarin should continue be reported via the Yellow Card Scheme (<a href=\"http://www.yellowcard.gov.uk\">www.yellowcard.gov.uk</a>).</p><p>Further informaton on <a href=\"http://www.nrls.npsa.nhs.uk/resources/?entryid45=59814\" target=\"_blank\">safer use of anticoagulant therapy</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Dec 2009, vol 3 issue 5: 7c.</em></p><p><a href=\"http://www.nrls.npsa.nhs.uk/resources/?entryid45=59814\" target=\"_blank\"></a>&nbsp;</p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>We continue to receive a substantial number of serious and fatal adverse event reports for <strong>warfarin</strong> through our Yellow Card Scheme.</p><p>We have recently reviewed the safety information for warfarin products to assess whether it is in line with information from Yellow Card reports, the current medical literature, and with current practice guidance. No new safety issues were identified during this review; however, the Summaries of Product Characteristics (SPCs) for all warfarin products are to be amended to give clearer and up-to-date advice to healthcare professionals. This update will also result in improved patient leaflets to ensure patients have consistent and appropriate information on this important medicine.</p><p>In particular, the core SPC provides advice on:</p><ul>\r\n\t\t\t<li>Timing of warfarin treatment after ischaemic stroke</li>\r\n\t\t\t<li>Management of the patient before surgical or dental procedures</li>\r\n\t\t\t<li>Patients at particular risk of haemorrhage</li>\r\n\t\t\t<li>Interactions with herbal products, foods, and food supplements</li>\r\n\t\t\t<li>Management of patients with significantly raised INR and/or haemorrhage</li></ul><p>The updated warfarin core safety information, along with further information on the review, is available in a <a href=\"http://http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON065505\" target=\"_blank\">public assessment report</a> on our website. In particular, healthcare professionals should ensure that they understand the contraindications to warfarin therapy, the relevant warnings, and the clinically significant drug interactions.</p><p>Serious and unexpected adverse effects relating to warfarin should continue be reported via the Yellow Card Scheme (<a href=\"http://www.yellowcard.gov.uk\">www.yellowcard.gov.uk</a>).</p><p>Further informaton on <a href=\"http://www.nrls.npsa.nhs.uk/resources/?entryid45=59814\" target=\"_blank\">safer use of anticoagulant therapy</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Dec 2009, vol 3 issue 5: 7c.</em></p><p><a href=\"http://www.nrls.npsa.nhs.uk/resources/?entryid45=59814\" target=\"_blank\"></a>&#160;</p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2009-12-01", 
  "date_last_modified": "2010-08-27", 
  "_assets": [], 
  "_item_id": 226, 
  "summary": "", 
  "body": "Article date: December 2009\n\nWe continue to receive a substantial number of serious and fatal adverse event reports for warfarin through our Yellow Card Scheme.\n\nWe have recently reviewed the safety information for warfarin products to assess whether it is in line with information from Yellow Card reports, the current medical literature, and with current practice guidance. No new safety issues were identified during this review; however, the Summaries of Product Characteristics (SPCs) for all warfarin products are to be amended to give clearer and up-to-date advice to healthcare professionals. This update will also result in improved patient leaflets to ensure patients have consistent and appropriate information on this important medicine.\n\nIn particular, the core SPC provides advice on:  \n  \n  * Timing of warfarin treatment after ischaemic stroke  \n  * Management of the patient before surgical or dental procedures  \n  * Patients at particular risk of haemorrhage  \n  * Interactions with herbal products, foods, and food supplements  \n  * Management of patients with significantly raised INR and/or haemorrhage  \n  \nThe updated warfarin core safety information, along with further information on the review, is available in a [public assessment report](http://http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON065505) on our website. In particular, healthcare professionals should ensure that they understand the contraindications to warfarin therapy, the relevant warnings, and the clinically significant drug interactions.\n\nSerious and unexpected adverse effects relating to warfarin should continue be reported via the Yellow Card Scheme ([www.yellowcard.gov.uk](http://www.yellowcard.gov.uk)).\n\nFurther informaton on [safer use of anticoagulant therapy](http://www.nrls.npsa.nhs.uk/resources/?entryid45=59814)\n\n \n\nArticle citation: Drug Safety Update Dec 2009, vol 3 issue 5: 7c.\n\n \n"
}